Individuals with metabolic disease (i.e. diabetes, NAFLD and obesity) display increased circulating levels of FGF-21; this has been attributed to a resistance to this hormone, and the administration of pharmacological doses of exogenous FGF-21 would overcome the resistance. This evidence concerns the gene FGF21 and Obesity.